This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miyazaki, Y. Articles by DeFronzo, R. A. Search for Related Content PubMed PubMed Citation Articles by Miyazaki, Y. Articles by DeFronzo, R. A.

Effect of Pioglitazone on Circulating Adipocytokine Levels and Insulin Sensitivity in Type 2 Diabetic Patients

University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas 78229-3900

Address all correspondence and requests for reprints to: Ralph A. DeFronzo, M.D., University of Texas Health Science Center, Diabetes Division, Room 3.380S, 7703 Floyd Curl Drive, San Antonio, Texas 78229-3900. E-mail: albarado{at}uthscsa.edu.

We examined the effect of pioglitazone (PIO) on circulating adipocytokine levels to elucidate the mechanisms by which thiazolidinediones improve insulin resistance in type 2 diabetes mellitus (T2DM). Twenty-three subjects with T2DM (age 54 ± 2 yr, body mass index 29 ± 1 kg/m²) were randomly assigned to receive placebo (n = 11) or PIO, 45 mg/d (n = 12), for 4 months. Before and after treatment, subjects received a 75-g oral glucose tolerance test (OGTT); euglycemic insulin clamp (40 mU/m²·min) with 3-³H-glucose; determination of fat mass (³H₂O); and measurement of fasting glucose, free fatty acids (FFAs), leptin, adiponectin, and TNF concentrations. After 4 months of PIO, fasting plasma glucose concentration ( = –2.7 mol/liter), mean plasma glucose during OGTT ( = –3.8 mol/liter), and hemoglobin A_1c ( = 1.7%) decreased (P < 0.05 vs. placebo) without change in fasting or post-OGTT plasma insulin levels. Fasting FFAs ( = 168 µmol/liter) and TNF ( = 0.7 pg/ml) concentrations decreased (P < 0.05 vs. placebo), whereas adiponectin ( = 8.7 µg/ml) increased (P < 0.01 vs. placebo). Despite the increase in body fat mass ( = 3.4 kg) after PIO, plasma leptin concentration did not change significantly. No changes in plasma glucose, FFAs, or adipocytokine levels were observed in placebo-treated subjects. During the insulin clamp, endogenous (hepatic) glucose production decreased ( = –2.67 µmol/fat-free mass·min, P < 0.05 vs. placebo), whereas metabolic clearance rate of glucose (MCR) increased ( = 0.58 ml/fat-free mass·min, P < 0.05 vs. placebo) after PIO. In all subjects, before and after PIO, the decrease in plasma FFA concentration was correlated with the changes in both endogenous (hepatic) glucose production (r = 0.47, P < 0.05) and MCR (r = –0.41, P < 0.05), whereas the increase in plasma adiponectin concentration was correlated with the change in endogenous (hepatic) glucose production (r = –0.70, P < 0.01) and MCR (r = 0.49, P < 0.05). These results suggest that the direct effects of PIO on adipose tissue to decrease plasma FFA levels and increase plasma adiponectin contribute to the improvements in hepatic and peripheral insulin sensitivity and glucose tolerance in patients with T2DM.

This article has been cited by other articles:

				H. Gotoh, T. Gohda, M. Tanimoto, Y. Gotoh, S. Horikoshi, and Y. Tomino Contribution of subcutaneous fat accumulation to insulin resistance and atherosclerosis in haemodialysis patients Nephrol. Dial. Transplant., June 17, 2009; (2009) gfp290v1. [Abstract] [Full Text] [PDF]

				A. Banga, R. Unal, P. Tripathi, I. Pokrovskaya, R. J. Owens, P. A. Kern, and G. Ranganathan Adiponectin translation is increased by the PPAR{gamma} agonists pioglitazone and {omega}-3 fatty acids Am J Physiol Endocrinol Metab, March 1, 2009; 296(3): E480 - E489. [Abstract] [Full Text] [PDF]

				B. Ravikumar, J. Gerrard, C. Dalla Man, M. J. Firbank, A. Lane, P. T. English, C. Cobelli, and R. Taylor Pioglitazone Decreases Fasting and Postprandial Endogenous Glucose Production in Proportion to Decrease in Hepatic Triglyceride Content Diabetes, September 1, 2008; 57(9): 2288 - 2295. [Abstract] [Full Text] [PDF]

				Z. Szocs, B. Brunmair, K. Stadlbauer, P. Nowotny, L. Bauer, A. Luger, and C. Furnsinn Age-Dependent Development of Metabolic Derangement and Effects of Intervention with Pioglitazone in Zucker Diabetic Fatty Rats J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 323 - 329. [Abstract] [Full Text] [PDF]

				E. Wajcberg, A. Sriwijitkamol, N. Musi, R. A. DeFronzo, and E. Cersosimo Relationship between Vascular Reactivity and Lipids in Mexican-Americans with Type 2 Diabetes Treated with Pioglitazone J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1256 - 1262. [Abstract] [Full Text] [PDF]

				A. Gastaldelli, E. Ferrannini, Y. Miyazaki, M. Matsuda, A. Mari, and R. A. DeFronzo Thiazolidinediones improve beta-cell function in type 2 diabetic patients Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E871 - E883. [Abstract] [Full Text] [PDF]

				A. M. Sharma and B. Staels Peroxisome Proliferator-Activated Receptor {gamma} and Adipose Tissue--Understanding Obesity-Related Changes in Regulation of Lipid and Glucose Metabolism J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 386 - 395. [Abstract] [Full Text] [PDF]

				M. J. Serlie, G. Allick, J. E. Groener, M. T. Ackermans, R. Heijligenberg, B. C. Voermans, J. M. Aerts, A. J. Meijer, and H. P. Sauerwein Chronic Treatment with Pioglitazone Does Not Protect Obese Patients with Diabetes Mellitus Type II from Free Fatty Acid-Induced Insulin Resistance J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 166 - 171. [Abstract] [Full Text] [PDF]

				T. Mazzone, P. M. Meyer, S. B. Feinstein, M. H. Davidson, G. T. Kondos, R. B. D'Agostino Sr, A. Perez, J.-C. Provost, and S. M. Haffner Effect of Pioglitazone Compared With Glimepiride on Carotid Intima-Media Thickness in Type 2 Diabetes: A Randomized Trial JAMA, December 6, 2006; 296(21): 2572 - 2581. [Abstract] [Full Text] [PDF]

				A. M. Bodles, A. Banga, N. Rasouli, F. Ono, P. A. Kern, and R. J. Owens Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E1100 - E1105. [Abstract] [Full Text] [PDF]

				N. B. Watts and D. A. D'Alessio Type 2 diabetes, thiazolidinediones: bad to the bone? J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3276 - 3278. [Full Text] [PDF]

				G. K. Bandyopadhyay, J. G. Yu, J. Ofrecio, and J. M. Olefsky Increased Malonyl-CoA Levels in Muscle From Obese and Type 2 Diabetic Subjects Lead to Decreased Fatty Acid Oxidation and Increased Lipogenesis; Thiazolidinedione Treatment Reverses These Defects. Diabetes, August 1, 2006; 55(8): 2277 - 2285. [Abstract] [Full Text] [PDF]

				E. H. Leiter, P. C. Reifsnyder, W. Zhang, H.-j. Pan, Q. Xiao, and J. Mistry Differential Endocrine Responses to Rosiglitazone Therapy in New Mouse Models of Type 2 Diabetes Endocrinology, February 1, 2006; 147(2): 919 - 926. [Abstract] [Full Text] [PDF]

				N. Rasouli, A. Yao-Borengasser, L. M. Miles, S. C. Elbein, and P. A. Kern Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression Am J Physiol Endocrinol Metab, January 1, 2006; 290(1): E42 - E46. [Abstract] [Full Text] [PDF]

				X. Li, P. A. Hansen, L. Xi, R. A. S. Chandraratna, and C. F. Burant Distinct Mechanisms of Glucose Lowering by Specific Agonists for Peroxisomal Proliferator Activated Receptor {gamma} and Retinoic Acid X Receptors J. Biol. Chem., November 18, 2005; 280(46): 38317 - 38327. [Abstract] [Full Text] [PDF]

				I. W Campbell Pioglitazone -- an oral antidiabetic agent and metabolic syndrome modulator. Can theory translate into practice? The British Journal of Diabetes & Vascular Disease, July 1, 2005; 5(4): 209 - 216. [Abstract] [PDF]

				J.-M. Fernandez-Real, J. Vendrell, and W. Ricart Circulating Adiponectin and Plasma Fatty Acid Profile Clin. Chem., March 1, 2005; 51(3): 603 - 609. [Abstract] [Full Text] [PDF]